title: Assessment and treatment of attention-deficit/hyperactivity disorder: part 2.
abstract: Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood. In part 1 of this article, information regarding primary care assessment of ADHD was presented. Part 2 focuses on best practice guidelines for treatment once the diagnosis has been established. For most children, successful treatment of ADHD requires a multicomponent approach comprised of patient and family psychoeducation, use of medications approved by the US Food and Drug Administration (eg, stimulants) and/or behavioral interventions, and management of any psychiatric comorbid conditions. Furthermore, as ADHD is a chronic illness, primary care physicians will need to frequently reassess their patients and make treatment adjustments as needed.
authors: William P
authors: WP
authors: French
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis* / Q000188:drug therapy*; D001521:Behavior Therapy / Q000379:methods; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000316:Adrenergic alpha-Agonists; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride